Stock Analysis

Shenzhen Kangtai Biological Products' (SZSE:300601) Promising Earnings May Rest On Soft Foundations

SZSE:300601
Source: Shutterstock

Unsurprisingly, Shenzhen Kangtai Biological Products Co., Ltd.'s (SZSE:300601) stock price was strong on the back of its healthy earnings report. We did some analysis and think that investors are missing some details hidden beneath the profit numbers.

View our latest analysis for Shenzhen Kangtai Biological Products

earnings-and-revenue-history
SZSE:300601 Earnings and Revenue History May 3rd 2024

How Do Unusual Items Influence Profit?

Importantly, our data indicates that Shenzhen Kangtai Biological Products' profit received a boost of CN„215m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. We can see that Shenzhen Kangtai Biological Products' positive unusual items were quite significant relative to its profit in the year to March 2024. As a result, we can surmise that the unusual items are making its statutory profit significantly stronger than it would otherwise be.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Shenzhen Kangtai Biological Products' Profit Performance

As we discussed above, we think the significant positive unusual item makes Shenzhen Kangtai Biological Products' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Shenzhen Kangtai Biological Products' underlying earnings power is lower than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. For example, we've discovered 2 warning signs that you should run your eye over to get a better picture of Shenzhen Kangtai Biological Products.

This note has only looked at a single factor that sheds light on the nature of Shenzhen Kangtai Biological Products' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

Valuation is complex, but we're helping make it simple.

Find out whether Shenzhen Kangtai Biological Products is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.